WB
H R
Endogenous
210
Rabbit IgG
#P0C0L4
720
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro148 of human C4-A/C4-B protein.
Background
Complement is a collection of soluble proteins secreted in the blood and other body fluids (1). As part of the innate immune system, complement proteins are involved in the clearance of pathogens and damaged cells in a process called opsonization, which results in the coating of a pathogen with antibodies and/or complement proteins to facilitate phagocytosis of debris or foreign pathogens. Complements are activated by a cascade of cleavage reactions, triggered initially by pattern recognition receptor-mediated detection of pathogens/debris. The cascade of cleavage-mediated products activate three distinct effector pathways, including inflammation, phagocytosis, and membrane attack that represent a coordinated defense of the host organism. Several complement proteins are encoded in the mammalian genome, designated by the capital letter C followed by a number, in order by their discovery. Complement C4-A and C4-B, encoded by the C4A and C4B genes, respectively, are the non-enzymatic components of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. The C4A/C4B genes generate C4-A/C4-B polypeptide proteins, composed of an alpha, beta, and gamma-chain subunits linked by disulfide bonds. The polypeptide protein can be further cleaved to generate a cascade of fragments to initiate the innate immune response. In addition to the innate immune response, several components of the complement system, including C4-A, have been implicated in brain development, as well as neurodevelopmental and neurodegenerative diseases. The complement system plays a role in microglial-dependent synapse pruning of excess synapses during development, particularly in the visual system (2). Additionally, complement-mediated synaptic pruning may also contribute to psychiatric diseases such as schizophrenia (3,4).
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
